Skip to content

Advancing Research, Securing Access

  • Chad Cipiti

By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…

Read more

TAGline Spring 2013

  • Chad Cipiti
Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.
Read more

Hepatitis C and the IL28B Gene

  • Chad Cipiti

April 2013 What predicts response to hepatitis C virus (HCV) treatment? Many things help predict the likelihood of being cured (called sustained virological response or SVR) by pegylated interferon (PEG-IFN) and ribavirin (RBV). Making sure to take all medications as…

Read more

Have a Heart, Save My liver!

  • Chad Cipiti

February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…

Read more

Data Deluge at AASLD

  • Chad Cipiti

by Tracy Swan It is difficult not to be dazzled by cure rates of up to 100% from interferon-free hepatitis C virus (HCV) trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012.…

Read more
TAGline Winter 2013 cover

TAGline Winter 2013

  • Chad Cipiti
Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.
Read more

Guide to Clinical Trials for People with Hepatitis C

  • Chad Cipiti
There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated.
Read more

2012 TAG Update

  • Chad Cipiti
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Read more

TAGline Fall 2012

  • Chad Cipiti
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
Read more
Back To Top